Home / Market News / $PEN
benzinga Corporate Catalyst Impact 75/100 ● positive

Penumbra Wins FDA Clearance For Lightning CAVT Technology To Treat Deep Vein Thrombosis, Backed By BOLT-DVT Trial Results

Oct 20, 2026, 1:04 PM UTC · Primary ticker $PEN

Penumbra announced FDA clearance for its Lightning CAVT technology to treat deep vein thrombosis (DVT), supported by positive results from the BOLT-DVT trial. This clearance expands the market opportunity for Penumbra's thrombectomy products and validates the safety and efficacy of their technology for a significant medical condition.

Penumbra, Inc. received FDA clearance for its Lightning computer assisted vacuum thrombectomy (CAVT) technology for the treatment of deep vein thrombosis (DVT). This is a significant development as it opens up a new, large market for Penumbra's innovative thrombectomy devices, backed by strong clinical trial data (BOLT-DVT). The clearance validates the safety and efficacy of their technology, potentially increasing adoption among healthcare providers. In the short term, this could lead to increased investor confidence and a positive stock reaction for PEN. Long-term, it positions Penumbra for sustained growth in the DVT treatment space, although competition from other medical device companies remains a key risk.

$PEN positive FDA clearance expands market and validates technology
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.